RESPONSE IN LUNG EXTRACELLULAR MATRIX TO ASBESTOS

$140,765P20FY2006RRNIH

University Of Montana, Missoula MT

Investigators

Linked publications, trials & patents

Paper 35792402 Paper 34929618 Paper 33093823 Paper 30188494 Paper 29046865 Paper 28893276 Paper 28609218 Paper 27865706 Paper 27864381 Paper 27771255 Paper 27594529 Paper 26641525 Paper 26563404 Paper 26555475 Paper 26286984 Paper 26272936 Paper 25782743 Paper 25701812 Paper 25592616 Paper 25495999 Paper 25449178 Paper 25433234 Paper 25364330 Paper 25230522 Paper 25179214 Paper 25175626 Paper 25093361 Paper 25054161 Paper 24852170 Paper 24822173 Paper 24706810 Paper 24486155 Paper 24304303 Paper 24297779 Paper 24225053 Paper 23963493 Paper 23936192 Paper 23746315 Paper 23649538 Paper 23635904 Paper 23574193 Paper 23555283 Paper 23551341 Paper 23526077 Paper 23480196 Paper 23363038 Paper 23216160 Paper 23094697 Paper 23066151 Paper 22956629 Paper 22875974 Paper 22743193 Paper 22735495 Paper 22697888 Paper 22686327 Paper 22607315 Paper 22577793 Paper 22471618 Paper 22432514 Paper 22302628 Paper 22295871 Paper 22276851 Paper 22273745 Paper 22183805 Paper 22113536 Paper 22085844 Paper 21976777 Paper 21948866 Paper 21916432 Paper 21866362 Paper 21855337 Paper 21829391 Paper 21399725 Paper 21151741 Paper 21144555 Paper 21131560 Paper 21097750 Paper 20889675 Paper 20797405 Paper 20701988 Paper 20576854 Paper 20564994 Paper 20495073 Paper 20463849 Paper 20350561 Paper 20211938 Paper 20207996 Paper 20161290 Paper 20155273 Paper 20149966 Paper 20149833 Paper 20081102 Paper 20044883 Paper 20044882 Paper 20039837 Paper 20017595 Paper 19830731 Paper 19822599 Paper 19777590 Paper 19774489

Abstract

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Attention to asbestos-related diseases has re-emerged due to the exposure of Libby, Montana residents to asbestos-contaminated vermiculite. Vermiculite distribution to over 200 sites nationwide and the long latent period for disease development make asbestos-related diseases a continuing public health issue. Previous studies demonstrated increased expression of Sparc and Adam28 in asbestos-exposed mouse lungs, including those exposed to the Libby amphibole. Both Sparc and Adam 28 encode proteins involved in the regulation of extracellular matrix (ECM) [unreadable] cell interactions, including the tissue remodeling similar to that occurring during fibrosis. The functions of these proteins make them exciting candidates for involvement in the fibrosis that occurs after asbestos exposure. Our hypothesis is that expression of the proteins encoded by Sparc and Adam28 are significant steps in the development of lung fibrosis after asbestos exposure. To test the hypothesis, the specific aims will 1) establish the in vivo gene and protein expression of Sparc and Adam28 in Sparc-null and matched wild-type mice after exposure to saline, the Libby amphibole, and crocidolite asbestos and 2) determine the response of primary lung fibroblast cultures isolated from the Sparc-null and matched wild-type mice to the same three treatments by examining ECM production. The proposed studies will enhance understanding of the interaction between cells and ECM in response to the Libby amphibole. With health risks faced by thousands of exposed individuals, the ultimate goal of these studies is to identify novel therapeutic targets for these and other similar lung diseases.

View original record on NIH RePORTER →